| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| ln Vitro |
Radioligand receptor binding assays using iodine-labeled monoiodinated PACAP(1-27) (human, sheep, and rat sources) confirmed the presence of PAC receptors on AR4-2J cells, as both PACAP(1-27) (human, sheep, and rat sources) and PACAP(1-38) could equivalently replace radioligand binding with a Kd value of 1-2 nM, while the potency of vasoactive intestinal peptide (VIP) was 1000 times lower. PACAP(1-27) (human, sheep, and rat sources) showed significant and higher sensitivity to VIP amino acid substitution. PACAP(1-27) (human, sheep, and rat sources) had the potency and binding affinity to stimulate the production of IP3 and cAMP in AR4-2J cells[2].
|
|---|---|
| ln Vivo |
This study investigated the inhibitory effect of pituitary adenylate cyclase activating peptide (PACAP (1-27), human, sheep, and rat) on the increase in total lung resistance (RL) induced by inhalation of allergens or histamine in anesthetized mechanically ventilated guinea pigs. Intravenous infusion of PACAP (1-27) (0.045-4.5 nmol/kg/min) dose-dependently reduced the increase in RL induced by inhalation of ovalbumin and histamine. At the highest dose, PACAP (1-27) completely blocked the increase in RL induced by ovalbumin and histamine. Infusion of PACAP (1-27) from humans, sheep, and rats and the β2-adrenergic receptor agonist salbutamol (0.045-4.5 nmol/kg/min) had similar inhibitory effects on the increase in RL, but salbutamol increased heart rate more than PACAP (1-27) from humans, sheep, and rats [3].
|
| References |
|
| Molecular Formula |
C144H225F3N40O41S
|
|---|---|
| Molecular Weight |
3261.68
|
| Related CAS # |
PACAP (1-27), human, ovine, rat
|
| Sequence |
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH2HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2
|
| SequenceShortening |
HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2
|
| Appearance |
White to off-white solid
|
| Synonyms |
PACAP 1-27 TFA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿和光照下。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~76.65 mM; with sonication)
H2O : ~12.5 mg/mL (~3.83 mM; with sonication) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (0.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (20.8 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (0.64 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; Need ultrasonic. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (0.64 mM)(saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3066 mL | 1.5330 mL | 3.0659 mL | |
| 5 mM | 0.0613 mL | 0.3066 mL | 0.6132 mL | |
| 10 mM | 0.0307 mL | 0.1533 mL | 0.3066 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
